Browsing by Author "Ala, A.A"

Now showing 1 - 2 of 2
  • Item
    Anti-anaemia Potential and Safety of Morinda lucida Leaf Extracts in Balb/c Mice Induced with Rhabdomyosarcoma Cells
    (2017-11) Ala, A.A; Abdulkareem, A.O; Akomolafe, D.F; Ohia, C.M.D
    Anaemia, a major health challenge, results from factors including dietary deficiencies and malaria. Although reports from previous studies show that Morinda lucida is effective in the treatment of anaemia resulting from these conditions, little information exist to suggest its beneficial effects in treating anaemia resulting from cancer. This study therefore examined the anti-anaemia potential of M. lucida leaf extracts in Balb/c mice inoculated with rhabdomyosarcoma (RD) cells. Forty mice inoculated intra-peritoneally with RD cells were randomly divided into eight groups: A (untreated); Treatment groups —B1, B2 and B3 (100, 200 and 300 mg/kg aqueous M. lucida extracts respectively); C1, C2 and C3 (100, 200 and 300 mg/kg M. lucida ethanolic extractsrespectively) and D (Cisplatin).Themice were treated for 2 weeks and thereafter, blood samples were collected through the orbital sinus for haematological and serum biochemical analyses. ComparedwithgroupA(3.25±0.03), ethanolic leaf extractsofM.lucida 3 increasedwhite blood cell count(x10 ul)significantly (p?0.05)in groups C1,C2, andC3 (5.45±0.03, 6.00±0.05, and 5.60±0.10 respectively) but there was no significantincrease of the packed cell volume in groups C andE.Comparedwith groupA, aspartate aminotransferase (AST)levels were significantly lower in all treatment groups, and alkalinephosphatase levels(ALP)significantly lower in group B. The treatments therefore did not improve all haematological parameters in RD cell-bearing mice but elicited increased immune responses, were safe at the doses administered andconsequentlymaybebeneficialincancer therapy.
  • Item
    Leaf extract of Morinda lucida improves pancreatic beta-cell function in alloxan-induced diabetic rats
    (Taylor & Francis, 2019-09-16) Abdulkareem, A.O; Igunnu, A; Ala, A.A; Olatunji, L.A
    Chemotherapy remains the utmost treatment for Type 1 diabetes (T1D) patients. This however, predisposes the patients to a wide range of serious complications, thus, the need for alternative therapeutic agents that target pancreatic β-cell function. This study investigated the effects of aqueous leaf extract of M. lucida (MLE) on β-cell dysfunction and atherogenic dyslipidaemia in alloxan-induced T1D in rats. Twenty-five Wister rats (156- 168g) were randomly divided into normal, diabetic, diabetic + glibenclamide (5 mg/kg), diabetic + 120 mg/kg MLE and diabetic + 240 mg/kg MLE groups (n = 5/ group). Treatments were via oral route for 14 days. Our findings revealed that, 120 mg/kg MLE significantly reduced hyperglycaemia, improved insulinaemia as well as β-cell function, and attenuated weight loss in alloxan-induced diabetic rats. The extract also attenuated (p < 0.05) atherogenic dyslipidaemia and malondialdehyde. The activities of the extract compared favourably with glibenclamide. This study suggested that, hypoglycaemic and mitigating effects of aqueous leaf extract of M. lucida on atherogenic dyslipidaemia and pancreatic β-cell dysfunction were through reduction in lipid peroxidation. The extract may therefore represent an effective source of novel drugs against TID and cardiovascular diseases. Further study is recommended, to explore the extract’s mechanism of oxidative repair